EXEL
$17.04
Exelixis
($.04)
(.23%)
EXEL
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  ($0.12)
Revenue:  $418.83 Mil
Tuesday
Jan 31
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EXEL reports earnings?
Beat
Meet
Miss

Where is EXEL's stock price going from here?
Up
Flat
Down
Stock chart of EXEL
Analysts
Summary of analysts' recommendations for EXEL
Score
Grade
Pivots
Resistance
$17.61
$17.42
$17.23

$17.04

Support
$16.85
$16.66
$16.47
Tweet
Growth
Description
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Peers
IncyteExact SciencesCharles River Laboratories InternationalCoherus Biosciences